AEGIS (Cancelled)
A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
- Medicine
- CSL112
- Population
- ASCVD
- Phase
- IIb
- Starting year
- 2014